• Home
  •  / Amarillo Biosciences

Amarillo Biosciences

OverviewSuggest Edit

Amarillo Biosciences is a specialty biopharmaceutical company working in Phase 2 human clinical trials with a well-characterized therapeutic agent, interferon-alpha, in a proprietary low-dose oral formulation.

TypePublic
HQAmarillo, USMap
Websiteamarbio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)2(-50%)
Revenue (FY, 2019)$11.7 K(-84%)
Share Price (Sept 2020)$0.2 (+23%)
Cybersecurity ratingAMore

Key People/Management at Amarillo Biosciences

Stephen T. Chen

Stephen T. Chen

Chairman & CEO

Amarillo Biosciences Office Locations

Amarillo Biosciences has an office in Amarillo
Amarillo, US (HQ)
4134 Business Park Dr
Show all (2)

Amarillo Biosciences Financials and Metrics

Amarillo Biosciences Revenue

Amarillo Biosciences's revenue was reported to be $11.73 k in FY, 2019
USD

Revenue (Q2, 2020)

484.0

Gross profit (Q2, 2020)

192.0

Gross profit margin (Q2, 2020), %

39.7%

Net income (Q2, 2020)

(302.0k)

EBIT (Q2, 2020)

(300.7k)

Market capitalization (22-Sept-2020)

8.2m

Closing stock price (22-Sept-2020)

0.2

Cash (30-Jun-2020)

172.8k
Amarillo Biosciences's current market capitalization is $8.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

58.4k530.0250.9k77.7k11.7k

Cost of goods sold

4.4k212.060.3k64.9k8.8k

Gross profit

54.0k318.0190.6k12.8k3.0k

Gross profit Margin, %

93%60%76%17%25%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.8k50.5k240.0240.050.04.4k250.5k56.6k250.014.9k4.1k606.04.8k15.2k484.0

Cost of goods sold

2.6k192.096.096.020.05.1k58.8k43.3k707.016.8k2.7k563.03.4k10.8k292.0

Gross profit

2.2k50.3k144.0144.030.0(700.0)191.7k13.3k(457.0)(1.9k)1.4k43.01.4k4.4k192.0

Gross profit Margin, %

46%100%60%60%60%(16%)77%23%(183%)(13%)33%7%30%29%40%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.8k7.3k6.5k134.1k2.0m1.3m409.0k

Accounts Receivable

Prepaid Expenses

6.6k13.7k62.0k23.6k26.6k32.1k

Inventories

1.1k184.014.7k22.7k4.1k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.4k1.1k22.5k3.7k302.07.4k4.6k9.1k3.8k1.5k279.0239.3k100.1k217.9k264.2k312.3k176.4k53.0k69.4k145.0k1.7m1.4m1.1m1.0m723.4k482.8k289.6k172.8k

Accounts Receivable

2.2k6.7k4.2k12.6k751.0

Prepaid Expenses

62.0k68.5k5.0k16.4k14.9k2.4k50.2k33.9k22.4k50.8k34.2k710.051.2k34.7k2.0k141.5k105.1k61.5k49.6k38.7k10.3k64.5k46.2k16.0k64.6k58.5k25.7k14.6k

Inventories

9.0k9.9k6.4k4.1k3.7k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(1.3m)(650.8k)(622.6k)(70.2k)(521.9k)(670.0k)(617.4k)(1.3m)(1.6m)

Depreciation and Amortization

16.6k15.6k16.1k3.0k19.8k26.0k40.0k56.2k22.2k

Inventories

(14.7k)(8.0k)22.7k(4.1k)

Accounts Payable

253.7k78.9k(61.8k)6.3k(8.6k)107.0k(9.5k)54.8k261.7k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(548.6k)(1.1m)(236.1k)(364.7k)(511.5k)(186.6k)(379.7k)(102.8k)(114.1k)

Cash From Operating Activities

(178.7k)(199.7k)(112.3k)(262.2k)(384.0k)(178.0k)(329.3k)(474.9k)(110.7k)(183.7k)(260.3k)(207.4k)(89.1k)1.7k(325.1k)(427.0k)(126.5k)(188.5k)(76.5k)(389.4k)(697.3k)(216.2k)(539.1k)(779.3k)(119.5k)(245.0k)

Purchases of PP&E

(47.7k)(47.7k)(4.9k)(1.6k)(1.6k)

Cash From Investing Activities

(1.2k)(2.4k)(3.2k)(4.1k)(211.0)(13.2k)(14.1k)(19.0)(7.8k)(7.8k)(11.1k)(11.6k)(8.6k)(68.1k)(102.2k)(5.3k)(25.8k)(39.9k)(1.7k)(2.1k)55.6k(1.6k)(1.6k)(2.0k)(1.3k)
show all
Show all financial metrics

Amarillo Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about about our premium products
SecurityScorecard logo

Amarillo Biosciences Online and Social Media Presence

Amarillo Biosciences's Trends

Embed Graph

Amarillo Biosciences News and Updates

September 10, 2020

Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board

Amarillo, TX - (NewMediaWire) - September 10, 2020 - Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), the world leader in low-dose non-injectable interferon research, is pleased to announce the appointment of Dr. Manfred Beilharz, Associate Professor at The University of Western Austral…
August 13, 2020

Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics

Amarillo, Texas - (NewMediaWire) - August 13, 2020 - Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it is taking steps to reaffirm its position as the world leader in low-dose non-injectable interferon research.  ABI will stre…
February 13, 2020

Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications

Amarillo, TX - (NewMediaWire) - February 13, 2020 - Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China licensing partner, Xiamen Weiyang Pharmaceutical Co., Ltd. (“Xiamen Weiyang”), has begun initiating the sharing of pr…
July 29, 2019

Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement

Amarillo, TX - (NewMediaWire) - July 29, 2019 - Amarillo Biosciences, Inc. (“ABI” or the “Company”), (OTCBB: AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical Co., Ltd., …
August 23, 2018

Amarillo Biosciences First-Half 2018 Business Update

Amarillo, TX - (NewMediaWire) - August 23, 2018 - Amarillo Biosciences, Inc. (ABI), (OTCBB: AMAR), a diversified healthcare company, today provided an update on its first-half 2018 results and recent business activities. “These past several quarters have continued to be an exciting period of execu…

 Amarillo Biosciences Frequently Asked Questions

  • Who are Amarillo Biosciences key executives?

    Amarillo Biosciences's key executives are Stephen T. Chen.

  • How many employees does Amarillo Biosciences have?

    Amarillo Biosciences has 2 employees.

  • What is Amarillo Biosciences revenue?

    Latest Amarillo Biosciences annual revenue is $11.7 k.

  • What is Amarillo Biosciences revenue per employee?

    Latest Amarillo Biosciences revenue per employee is $5.9 k.

  • Who are Amarillo Biosciences competitors?

    Competitors of Amarillo Biosciences include Obsidian Therapeutics, Z Factor and Mymetics.

  • Where is Amarillo Biosciences headquarters?

    Amarillo Biosciences headquarters is located at 4134 Business Park Dr, Amarillo.

  • Where are Amarillo Biosciences offices?

    Amarillo Biosciences has an office in Amarillo.

  • How many offices does Amarillo Biosciences have?

    Amarillo Biosciences has 2 offices.